Overall, NfL response across AD, HD and ALS trials have been mixed, but it is likely to be relevant that the most successful clinical outcomes, e.g. SOD1 ALS trial, are associated with early significant reductions in NfL. The gene discussed is NEFL; the disease is Alzheimer disease.